Skip to the page

Data / Form D filings / AirNexis Therapeutics, Inc.

AirNexis Therapeutics, Inc.: Form D filing

AirNexis Therapeutics, Inc., a biotechnology company in Palo Alto, CA, filed a Form D with the SEC in 2026. The latest, on March 9, 2026, reports $62 million sold of a $200 million offering to 13 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
1001 PAGE MILL ROAD BUILDING 4, SUITE 200B, Palo Alto, CA, 94304
Phone
(619) 604-7904
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2024
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2116194

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Mar 9, 2026New notice$200,000,000$62,000,000$138,000,00013Jan 9, 2026sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Maria FardisExecutive Officer, Director
Anna ChenDirector
Evan CaplanDirector
Colin WalshDirector
Jill CarrollDirector
James LiExecutive Officer, Director

Other biotechnology companies in California that filed recently

Every Form D from the week of Mar 9, 2026 · All recent filings in California · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what AirNexis Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.